Bravo F J, Bourne N, Harrison C J, Mani C, Stanberry L R, Myers M G, Bernstein D I
Division of Infectious Diseases, Children's Hospital Research Foundation, Cincinnati, Ohio 45229, USA.
J Infect Dis. 1996 Jan;173(1):1-6. doi: 10.1093/infdis/173.1.1.
Neonatal herpes simplex virus (HSV) infection produces severe disease with unacceptable morbidity and mortality with current antiviral therapies. The effect of therapy with passive anti-HSV antibody and acyclovir was evaluated using a guinea pig model of neonatal HSV. Newborn animals were inoculated intranasally and treated with acyclovir (60 mg/kg/day) or antibody (or both), beginning on days 0, 2, or 3 after HSV-2 inoculation. Acyclovir alone was effective only when begun on day 0, and antibody alone was effective when begun on or before day 2. Only combination therapy was effective on day 3, reducing mortality from 82% (14/17) in controls to 44% (7/16; P < .05). Combined therapy also significantly reduced the duration of skin, eye, and mouth disease and respiratory symptoms but not recurrent disease. These data suggest that addition of antibody therapy to acyclovir may improve the outcome of neonatal HSV disease.
新生儿单纯疱疹病毒（HSV）感染会引发严重疾病，采用当前的抗病毒疗法治疗时，其发病率和死亡率均令人难以接受。使用新生儿HSV豚鼠模型评估了被动抗HSV抗体与阿昔洛韦联合治疗的效果。新生动物经鼻接种病毒，并在接种HSV-2后的第0、2或3天开始用阿昔洛韦（60毫克/千克/天）或抗体（或两者联用）进行治疗。单独使用阿昔洛韦仅在第0天开始治疗时有效，单独使用抗体在第2天或第2天之前开始治疗时有效。只有联合治疗在第3天有效，可将死亡率从对照组的82%（14/17）降至44%（7/16；P<0.05）。联合治疗还显著缩短了皮肤、眼睛和口腔疾病以及呼吸道症状的持续时间，但对复发性疾病无效。这些数据表明，在阿昔洛韦治疗基础上加用抗体治疗可能会改善新生儿HSV疾病的治疗效果。
